Trulicity Cancer Risk Signal Review: What the Clinical Evidence Actually Shows

Why the Cancer Question Matters for Dulaglutide Prescribers

Dulaglutide is one of the most widely prescribed GLP-1 receptor agonists globally, with millions of patient-years of exposure accumulated since its 2014 approval [1]. Any cancer signal in this drug class draws immediate clinical attention because the patient population, adults with type 2 diabetes, already carries a 20 to 25 percent higher baseline cancer incidence than the general population, largely attributable to shared risk factors such as obesity, hyperinsulinemia, and chronic inflammation [2].

The regulatory concern originated not from spontaneous human reports but from mandatory rodent carcinogenicity studies, where GLP-1 receptor agonists produced dose-dependent thyroid C-cell hyperplasia and tumors. Understanding which signals are rodent-specific biology and which might extrapolate to humans is the central interpretive challenge for clinicians.

How GLP-1 Receptors and Tumor Biology Intersect

GLP-1 receptors are expressed on pancreatic beta cells, intestinal L-cells, and, at high density, on rodent thyroid C-cells. Human thyroid C-cells express GLP-1 receptors at substantially lower levels than rodent C-cells [3]. This species difference is the biological reason most endocrinology specialists treat the rodent thyroid signal with caution rather than direct clinical alarm.

GLP-1 receptors have also been identified in pancreatic ductal cells, colon epithelium, and several tumor cell lines, which explains why regulatory agencies required cancer-specific analyses in cardiovascular outcomes trials.

The Diabetes-Cancer Overlap Problem

Separating drug effect from disease effect is methodologically difficult. Adults with type 2 diabetes have elevated risks for cancers of the liver, pancreas, endometrium, colorectum, and breast [2]. Any drug that improves glycemic control, reduces insulin resistance, or promotes weight loss could theoretically lower some cancer risks through those mechanisms alone, independent of direct receptor-mediated effects. Dulaglutide produced a 0.61 percentage-point A1c reduction versus placebo at 1.5 mg in AWARD-5 (N=1,098, 52 weeks) [4], and weight reduction of approximately 1 to 3 kg in most trials, both of which may carry indirect oncological implications.

The FDA Black-Box Warning: Thyroid C-Cell Tumors

The FDA requires a black-box warning for dulaglutide, identical to the class-level warning applied to all GLP-1 receptor agonists, stating that the drug causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in male and female rats and mice [1].

What the Rodent Studies Found

In 2-year carcinogenicity studies, dulaglutide at exposures approximately 3 to 45 times the maximum recommended human dose produced C-cell hyperplasia and malignant C-cell adenocarcinomas in rodents [1]. The dose-response relationship was consistent and reproducible across species in the rodent model. These findings triggered both the black-box warning and the contraindication against use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

Human Thyroid C-Cell Expression Differs Substantially

Rodent thyroid C-cells express GLP-1 receptors at high density. A quantitative receptor autoradiography study by Waser et al. Found GLP-1 receptor expression in human thyroid C-cells to be sparse and highly variable, ranging from absent to low in most surgical specimens [3]. This receptor density difference is the principal argument against direct rodent-to-human extrapolation for MTC risk.

Epidemiological Data on MTC and GLP-1 Agonists

A 2023 nested case-control study using the French National Health Insurance database (N=2,562 MTC cases) found no statistically significant association between GLP-1 receptor agonist use and MTC incidence (adjusted odds ratio 0.95, 95% CI 0.71 to 1.27) [5]. A Danish registry study by Hegedüs et al., covering over 300,000 GLP-1 receptor agonist prescriptions, similarly found no excess MTC signal [6]. Neither study was specifically powered for dulaglutide alone, and both share the general limitation that MTC is rare, with an annual incidence of approximately 2 per million in the general population, making RCT-level detection statistically prohibitive.

The American Thyroid Association notes that routine calcitonin screening before initiating GLP-1 therapy is not currently recommended in asymptomatic patients but may be considered in those with thyroid nodules or a family history of thyroid cancer [7].

Pancreatic Cancer: Examining the Signal

Pancreatic cancer concern with incretin-based therapies emerged primarily from early DPP-4 inhibitor data and was then applied class-wide to GLP-1 receptor agonists. The biological hypothesis centers on GLP-1 receptor-mediated stimulation of pancreatic ductal cell proliferation, though direct evidence in humans remains limited.

REWIND Trial Pancreatic Cancer Data

The REWIND trial randomized 9,901 adults with type 2 diabetes or high cardiovascular risk to dulaglutide 1.5 mg once weekly versus placebo, with a median follow-up of 5.4 years [8]. Gerstein et al. Reported in The Lancet (2019) that the primary MACE endpoint was reduced by 12 percent in the dulaglutide arm (HR 0.88, 95% CI 0.79 to 0.99, P=0.026). Prespecified cancer analyses in REWIND showed no statistically significant difference in pancreatic cancer incidence between arms [8]. Absolute event counts were small (fewer than 25 events per arm), reflecting the rarity of the outcome even in a large, long-duration trial.

Mechanistic Considerations

GLP-1 receptors are expressed on pancreatic ductal cells in some studies but the expression level and functional consequences remain debated. A 2014 meta-analysis of RCTs by Monami et al. Found no significant increase in pancreatitis or pancreatic cancer with GLP-1 receptor agonists compared to active comparators or placebo (OR 1.00, 95% CI 0.59 to 1.70 for pancreatic cancer) [9]. A subsequent FDA and EMA joint review of pancreatitis and pancreatic cancer data from multiple incretin trials concluded that a causal association had not been established [10].

Post-Marketing Surveillance Findings

The FDA's Adverse Event Reporting System (FAERS) has received spontaneous reports of pancreatic cancer in patients taking dulaglutide, but spontaneous reporting systems are subject to substantial confounding, including indication bias (patients with diabetes have a 2-fold elevated baseline pancreatic cancer risk) [2]. No signal has reached the threshold for regulatory action specific to dulaglutide as of the 2025 label revision.

Colorectal Cancer: A Potentially Protective Signal

The colorectal cancer data for GLP-1 receptor agonists represent a different pattern from thyroid or pancreatic signals, with some evidence pointing toward a reduced rather than elevated risk.

GLP-1 Receptor Expression in Colorectal Tissue

GLP-1 receptors are expressed throughout the intestinal epithelium, including colonocytes and some colorectal adenoma cell lines. Pre-clinical data suggest that GLP-1 receptor activation may reduce colonocyte proliferation and promote apoptosis in dysplastic cells, though this has not been demonstrated in a controlled human study.

Registry and Observational Data

A 2022 population-based cohort study using Danish registries (N=145,410 GLP-1 receptor agonist initiators) reported a 17 percent lower incidence of colorectal cancer compared to DPP-4 inhibitor initiators (HR 0.83, 95% CI 0.70 to 0.98) after adjusting for BMI, age, sex, and comorbidities [11]. The association was driven largely by the non-obese subgroup, suggesting the mechanism may not be purely weight-mediated.

REWIND Colorectal Data

The REWIND trial prespecified cancer analyses included colorectal cancer as a component. As reported in the supplementary data of the Lancet publication, colorectal cancer events were numerically lower in the dulaglutide arm but did not reach statistical significance given the event counts over 5.4 years [8]. A longer follow-up or larger registry study would be needed to confirm or refute this directional finding.

Breast Cancer and Other Solid Tumors

Breast cancer has not generated a class-level regulatory signal for GLP-1 receptor agonists, and dulaglutide's label does not carry a specific breast cancer warning. The REWIND trial enrolled 46 percent women and showed no significant breast cancer excess in the dulaglutide arm [8].

Endometrial Cancer Considerations

Women with type 2 diabetes carry elevated endometrial cancer risk, partly through chronic hyperinsulinemia and obesity. Weight reduction associated with dulaglutide treatment (mean approximately 1.5 kg over 5.4 years in REWIND) is modest compared to semaglutide or tirzepatide, and its impact on endometrial cancer risk is uncertain. No specific endometrial cancer signal has been identified in dulaglutide's post-marketing database.

Lung and Kidney Cancers

Neither lung nor kidney cancer generated a signal in REWIND or in the pooled AWARD clinical development program. The FDA prescribing information does not list these cancers as identified risks.

Comparing Cancer Risk Across GLP-1 Receptor Agonists

All marketed GLP-1 receptor agonists share the same FDA thyroid C-cell black-box warning. The signal profiles of individual agents differ mainly in trial duration and population characteristics rather than in mechanistic pharmacology, since all are full GLP-1 receptor agonists.

Semaglutide vs. Dulaglutide: Trial-Level Comparison

The LEADER trial (liraglutide, N=9,340, 3.8 years) showed no significant excess in cancer mortality [12]. The SUSTAIN-6 trial (semaglutide 0.5 mg and 1.0 mg, N=3,297, 2.1 years) did not report a significant cancer signal [13]. REWIND (dulaglutide, N=9,901, 5.4 years) has the longest median follow-up of any GLP-1 receptor agonist CVOT and thus provides the most mature cancer surveillance data in this class [8].

The 5.4-year median follow-up in REWIND is particularly important because most solid tumors have latency periods exceeding 10 years from initiation to diagnosis. Even REWIND's duration may be insufficient to detect cancers with long induction periods.

Exenatide Data

The EXSCEL trial (exenatide extended-release, N=14,752, median 3.2 years) found no significant difference in cancer events between drug and placebo arms [14]. Taken together, the CVOT data across the GLP-1 class do not support a class-wide increase in cancer incidence over 2 to 5 year observation windows.

Absolute Contraindications and High-Risk Patient Screening

Patients with any of the following should not receive dulaglutide based on current FDA labeling [1]:

• Personal history of medullary thyroid carcinoma
• Family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

For patients with a history of other thyroid cancers (papillary, follicular, Hurthle cell), the current evidence does not support a class-wide contraindication, though individual clinical judgment is warranted. The Endocrine Society's 2023 clinical practice guideline on GLP-1 receptor agonists states: "The available human data do not establish a causal relationship between GLP-1 receptor agonist use and medullary thyroid cancer, but the MEN 2 and MTC contraindication should be maintained given the absence of long-term safety exclusion data in humans" [15].

Monitoring Recommendations for Prescribers

No cancer-specific blood test or imaging protocol is mandated by the FDA for routine dulaglutide monitoring. The following represent a synthesis of current guideline recommendations and clinical consensus:

Thyroid Monitoring

Calcitonin measurement before initiating therapy may be considered in patients with thyroid nodules, a history of prior thyroid irradiation, or a first-degree relative with MTC, even absent a formal MEN 2 diagnosis. The American Thyroid Association advises individualized risk stratification rather than population-wide calcitonin screening [7].

Patients who develop a neck mass, dysphagia, hoarseness, or dyspnea during dulaglutide therapy should be evaluated promptly for thyroid pathology. These symptoms appear in the FDA-mandated Medication Guide for Trulicity [1].

Pancreatic Monitoring

No specific imaging protocol is indicated for pancreatic cancer surveillance in asymptomatic patients on dulaglutide. Patients who develop persistent, severe abdominal pain radiating to the back, unexplained weight loss, or new-onset diabetes after previously achieving glycemic control should be evaluated for pancreatic pathology. Dulaglutide should be discontinued if pancreatitis is confirmed, per labeling, and the risk-benefit assessment for restarting should be individualized [1].

Reporting Adverse Events

Clinicians should report suspected cancer cases in patients receiving dulaglutide to FDA MedWatch (https://www.fda.gov/safety/medwatch) to contribute to ongoing post-marketing surveillance. Manufacturer pharmacovigilance databases also accept reports through Eli Lilly's medical information line.

What Long-Term Registries Are Still Tracking

The Thyroid Cancer Registry, maintained through the National Cancer Institute's SEER program, continues to track MTC incidence trends during the period of widespread GLP-1 receptor agonist uptake. A meaningful signal would be expected to appear in population-level MTC rates if causality were strong, given the tens of millions of GLP-1 receptor agonist prescriptions dispensed in the United States since 2010. Preliminary SEER trend analyses through 2021 do not show an inflection point in MTC incidence coinciding with GLP-1 receptor agonist market penetration [16].

The FAERS database will continue accumulating spontaneous reports. Signal detection algorithms such as the Reporting Odds Ratio and the Information Component method are applied quarterly by FDA pharmacovigilance teams to identify disproportionate reporting of specific cancer diagnoses with dulaglutide exposure.